烟台东诚药业集团股份有限公司 关于控股子公司获得放射性药品 生产许可证的公告

Group 1 - The company, Yantai Dongcheng Pharmaceutical Group Co., Ltd., has received a production license for radioactive drugs for its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. [1] - The production license is specifically for the radiopharmaceutical fluorine-18 labeled peptide injection, which is intended for product registration application use only [1] - The license is valid until November 25, 2030, and the production will take place at Nanjing Jiangyuan Andike Positron Research and Development Co., Ltd. [1] Group 2 - The company anticipates that the acquisition of the production license will not have a significant impact on its current performance, as commercial production can only commence after obtaining the drug marketing approval number [1] - The pharmaceutical industry is characterized by high technology, high risk, and high added value, making drug sales susceptible to changes in industry policies and market conditions [2]